Latest Antibody Stories
PROVIDENCE, R.I. and SAN DIEGO, April 24, 2013 /PRNewswire/ -- Full article - http://bit.ly/EpiAtla13 EpiVax Inc., an unique immunology company with a strong focus on immunogenicity mitigation and BioAtla, LLC, a San Diego headquartered antibody therapeutics developer, today announced a collaborative agreement to incorporate EpiVax's proprietary immunogenicity screening technology into BioAtla's antibody Express Humanization(TM) platform. (Logo:...
LA JOLLA, Calif., April 22, 2013 /PRNewswire-USNewswire/ -- In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells. Current techniques for turning patients' marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from...
CAMBRIDGE, England, April 22, 2013 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company, announced today an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse(TM) human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL...
DUBLIN, Ireland, April 16, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013 [http://www.researchandmarkets.com/research/7rg77r/antibody ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of...
MONROVIA, Calif. and MELBOURNE, Australia, April 16, 2013 /PRNewswire/ -- Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend technology to optimize the performance of CSL's monoclonal antibodies. Under the agreement CSL will be granted an exclusive license to utilize Xencor's proprietary Xtend(TM) half-life extension technology in its program against an undisclosed target. Xencor will...
BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...
ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX(TM) (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. (Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO) "We anticipate the...
Brett Smith for redOrbit.com - Your Universe Online When HIV enters the human body, it begins an arms race with the immune system which is constantly attempting to develop new ways to destroy the invader. Unfortunately, the body is at some point overwhelmed by a multitude of HIV mutations before the immune system is able to develop a superweapon against the virus. However, some immune systems do develop a superweapon called "broadly neutralizing antibodies” a few years after the...
WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong). Under the terms of the collaboration, Hengrui will fund and lead all...
NORCROSS, Ga., April 3, 2013 /PRNewswire/ -- RayBiotech, Inc. announced today that the application of its Mouse Cytokine Antibody Array has enabled the identification of key factors involved in the dissemination of leprosy infection in humans. This seminal research was conducted by Dr. Anura Rambukkana and colleagues at the Medical Research Council Center for Regenerative Medicine, University of Edinburgh and the Rockefeller University in New York. In this study, Dr. Rambukkana's...
